https://www.ajmc.com/view/fda-grants-priority-review-to-dapagliflozin-for-ckd
The FDA decision on dapaglifozin for CKD is expected in the second quarter of 2021.
priority reviewfdagrantsdapagliflozinckd
https://www.ajmc.com/view/merck-gets-priority-review-in-nda-for-vericiguat
The company said FDA has set a date of January 20, 2021, for action under the Prescription Drug User Fee Act.
priority reviewmerckgetsndavericiguat
https://www.fda.gov/regulatory-information/search-fda-guidance-documents/list-highest-priority-devices-human-factors-review?utm_medium=email&utm_source=govdelivery
Informs medical device manufacturers which device types should have human factors data included in premarket submissions (i.e., for PMA, 510(k)).
list ofhuman factorshighestprioritydevices
https://www.ajmc.com/view/fda-grants-ruxolitinib-priority-review-to-treat-chronic-gvhd
The FDA has granted priority review of the supplemental New Drug Application for ruxolitinib for the treatment of steroid-refractory chronic graft-versus host...
priority reviewfdagrantsruxolitinibtreat
https://www.merck.com/news/patritumab-deruxtecan-granted-priority-review-in-the-u-s-for-certain-patients-with-previously-treated-locally-advanced-or-metastatic-egfr-mutated-non-small-cell-lung-cancer/
Submission based on HERTHENA-Lung01 results showing patritumab deruxtecan demonstrated clinically meaningful and durable responses in patients with advanced...
the u spatritumab deruxtecanpriority reviewgranted
https://www.ajmc.com/view/glasdegib-receives-priority-review-based-on-results-it-nearly-doubles-os-in-aml
Based on trial results that showed glasdegib, an investigational oral smoothened inhibitor, nearly doubled overall survival (OS) in patients with previously...
priority reviewglasdegibreceivesbasedresults
https://prioritycareshs.com/avast-vpn-review/
In terms of privacy the avast.vpn review is off to an excellent beginning with its no-logging policy. It also has a good score for its extensive list of...
avast vpnhome servicesreviewprioritycares
https://www.prnewswire.com/news-releases/eiger-biopharmaceuticals-announces-fda-acceptance-of-nda-for-filing-with-priority-review-of-zokinvy-lonafarnib-for-treatment-of-progeria-and-progeroid-laminopathies-301062068.html
/PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for serious rare and...
eigerbiopharmaceuticalsannouncesfdaacceptance